SciVision Biotech Inc. Secures Taiwan Invention Patent, Reinforcing Leadership in Hyaluronic Acid Technologies

SciVision Biotech Inc. Secures Taiwan Invention Patent, Reinforcing Leadership in Hyaluronic Acid Technologies

SciVision Biotech Inc. has been granted a Taiwan invention patent (Patent No. I920698), titled “Method for Manufacturing Crosslinked Hyaluronic Acid Gel Containing Triamcinolone and Crosslinked Hyaluronic Acid Gel Thereof.” This patented technology is designed for the production of triamcinolone-containing crosslinked hyaluronic acid (HA) gels intended for the treatment of osteoarthritis patients.

Triamcinolone is a type of corticosteroid commonly used in intra-articular injections to relieve inflammation and pain associated with osteoarthritis. Corticosteroids may be naturally produced by the adrenal cortex or synthetically manufactured for medical applications. When combined with crosslinked hyaluronic acid for joint injection, the therapeutic effect can be further enhanced. Corticosteroids are known to provide rapid pain relief during the first few days following injection.

Leveraging SciVision’s proprietary CHAP crosslinking platform technology together with its newly developed uniform particle dispersion technology, triamcinolone can be evenly distributed throughout the crosslinked HA gel matrix. The resulting formulation enables sustained drug release, thereby prolonging the anti-inflammatory and analgesic effects of the corticosteroid.

This invention patent represents a key technological advancement in drug-device combination products based on crosslinked hyaluronic acid matrices. The newly granted patent marks a significant breakthrough for SciVision in the development and manufacturing of HA-based drug-containing products. The patent scope covers both manufacturing methods and composition claims, providing strong protection against competitive development of similar products and further strengthening SciVision’s leadership position in the hyaluronic acid market.